Mental Health DailyResearch. Evidence. Perspective.Published research on esketamine.
A 99-patient randomized trial found that adding esketamine to sufentanil patient-controlled analgesia lowered postoperative depression and anxiety scores at 24 and 72 hours after colorectal …
Read articleA 2026 national survey of Dutch emergency physicians found wide variation in first-line medication choices for extreme agitation: without intravenous access, 34.7% preferred midazolam, 23.1%…
Read articleIntranasal esketamine — FDA-approved for treatment-resistant depression in 2019 — failed cost-effectiveness benchmarks against four cheaper third-line options in a 2026 Hong Kong modeling st…
Read articleA 2026 retrospective case series of 22 adults with treatment-resistant depression and comorbid PTSD found that trauma re-experiencing during intranasal esketamine disappeared over later sess…
Read articleKetamine and its S-enantiomer esketamine (sold as Spravato) are now established treatments for treatment-resistant depression and acute suicidality. The standard safety pitch from sponsors a…
Read articleTreatment-resistant depression (TRD) represents a significant challenge in mental health care, often leaving patients and clinicians in a difficult position after traditional treatments fail…
Read articleResearch suggests that upwards of 16 million American adults (6.7% of the adult population) are afflicted with major depressive disorder (MDD), a neuropsychiatric condition characterized by …
Read article
